Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year
D Houpe1, M Peltier, A Cohen-Solal
1Department of Cardiology, South Hospital, Amiens, France.
Insights
Treatment for heart failure (HF) with reduced ejection fraction largely uses diuretics and ACE inhibitors. However, beta-blocker use remains low in both patient numbers and prescribed dosages, indicating a need for better guideline adherence.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Guidelines for heart failure (HF) with left ventricular systolic dysfunction exist but are not consistently applied in practice.
- The ETICS study aimed to assess medical treatment adherence in HF patients post-hospitalization.
Purpose of the Study:
- To evaluate the prescription patterns of HF medications at discharge and one year post-hospitalization.
- To identify areas of underutilization of guideline-recommended therapies.
Main Methods:
- Prospective inclusion of 179 patients (63% male, mean age 69±13 years) with ejection fraction ≤ 40%.
- Primary etiology of HF was ischemic heart disease (44%).
- Medication use and dosages were recorded at discharge and 1-year follow-up.
Main Results:
- Loop diuretics (95%) and ACE inhibitors (82%) were highly prescribed at discharge.
- Beta-blocker prescription increased from 25% at discharge to 41% at 1 year, but dosages remained suboptimal (26% and 35% of recommended, respectively).
- Spironolactone use was consistent (35-37%), while digitalis and nitrates saw decreased use.
Conclusions:
- Diuretics and ACE inhibitors are widely used for HF with left ventricular systolic dysfunction.
- Beta-blockers are underutilized in terms of patient numbers and prescribed doses.
- Enhanced dissemination of clinical practice guidelines is crucial for improving HF management.
Background:
The treatment of heart failure (HF) due to left ventricular systolic dysfunction has been defined in recent guidelines, but these guidelines are not always applied in routine clinical practice. One of the objectives of the ETICS study was to evaluate medical treatment at discharge and after 1 year in patients hospitalised for a first episode of congestive HF due to left ventricular systolic dysfunction in 2000.
Methods:
One hundred and seventy nine patients (63% males, mean age of 69+/-13 years) with an ejection fraction < or = 40% were prospectively included. The main aetiology was ischaemic heart disease (44%).
Results:
The drugs prescribed at discharge and at one year, respectively, were loop diuretics in 95% and 91% of cases, angiotensin-converting enzyme (ACE) inhibitors in 82% and 75%, spironolactone in 35% and 37%, beta-blockers in 25% and 41%, digitalis glycosides in 34% and 30% of cases, and nitrates in 20% and 16% of cases. ACE inhibitors were prescribed at discharge and at 1 year at dosages reaching 64+/-29% and 72+/-30% of the recommended doses, respectively, and beta-blockers were prescribed at 26+/-16% and 35+/-25% of recommended doses, respectively.
Conclusion:
Diuretics and ACE inhibitors are largely prescribed in HF due to left ventricular systolic dysfunction, followed by spironolactone. Beta-blockers are still underused both in terms of the rate of patients receiving them and the daily doses. These results highlight the value of continuing to widely circulate official practice guidelines in order to improve the management of HF due to left ventricular systolic dysfunction.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

